This report was first published by Endpoints News. To see the original version, click here
Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world.
The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as $287 million in a Series D1 round, the company said Thursday. The cash will help advance its lead drug program, a GLP-1 pill initially developed by the China biotech Vincentage. Corxel acquired ex-China rights to that program in 2024 and plans to launch a second US-based Phase 2 study this year.
您已阅读18%（594字），剩余82%（2695字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。